Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Tumori|January 20, 2005
Narrower surgical margins might be sufficient in invasive horizontal growth phase melanomaAldo Bono, Cesare Bartoli, Marzia Baldi, et al.
European Urology|December 16, 2010
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al.
European Urology|January 9, 2007
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trialLuigi Dogliotti, Giacomo Cartenì, Salvatore Siena, et al.
Physics in Medicine and Biology|November 3, 2005
Automated segmentation of pigmented skin lesions in multispectral imagingMauro Carrara, Stefano Tomatis, Aldo Bono, et al.
Dermatology (Basel, Switzerland)|November 22, 2002
Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometryAldo Bono, Cesare Bartoli, Natale Cascinelli, et al.
Pediatrics|March 3, 2005
Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institutionAndrea Ferrari, Aldo Bono, Marzia Baldi, et al.
Tumori|July 30, 2016
Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experienceStefano Cavalieri, Lorenza Di Guardo, Carolina Cimminiello, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Molecular prostate cancer pathology: current issues and achievementsJack A Schalken, Anders Bergh, Aldo Bono, et al.
European Urology|August 6, 2013
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCGMaurizio Brausi, Jorg Oddens, Richard Sylvester, et al.
Cancer Research|May 17, 2003
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanomaRoberta Mortarini, Adriano Piris, Andrea Maurichi, et al.
Pageof 3